Sanofi has announced plans to invest approximately €1bn to build a new insulin production base in China.

Sanofi unveiled a plan to build a $1 billion manufacturing site in Beijing while completing construction at a plant in ...

Novo will drop its U.S. list price for its Fiasp by 75% and for Tresiba by 72%, the Danish company said in a release. The new ...

Long-Acting Insulin Analogs Dominate the Global Biosimilar Market, While Rapid-Acting Insulins Lead in Growth Potential ...

Gymnast Jordan Chiles was engaged by Sanofi to advocate for type 1 diabetes screenings. She has a personal connection to the ...

Earlier this month, non-profit drugmaker Civica Rx pledged to launch biosimilars of three big-selling insulin products in the US – Sanofi's Lantus, Novo Nordisk's Novolog and Eli Lilly's Humalog ...

The biosimilars – which will be interchangeable with Sanofi's Lantus (insulin glargine), Novo Nordisk's Novolog (insulin aspart) and Eli Lilly's Humalog (insulin lispro) – will be priced at no ...

12 February 2018, Sanofi India announced the launch of its new insulin product Toujeo. Toujeo is a once-daily, long-acting basal analog insulin that improves glycemic control in adults with type 1 ...

Pharmaceutical and biotech businesses were enthusiastic about the UPC before the court opened, but so far there has only been ...

Health2Sync's patient-centric app, combined with automated patient engagement, offers personalized lifestyle recommendations ...

In a report released today, Peter Welford from Jefferies maintained a Sell rating on Novo Nordisk (0QIU – Research Report). The company’s ...